Australia’s health expenditure totalled Euros 58.6 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 2007–2008, which is the same percentage of GDP as the previous year. Australia’s health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.
Australian healthcare reform
Home/Policies & Legislation
|
Posted 17/12/2010
0
Post your comment

With the election of the government in 2007, a National Health and Hospitals Reform Commission was established to develop a long-term health reform plan and broaden the healthcare agreements between central government and the US. Under the proposed legislation, central government will retain more tax revenues from the states and territories, becoming the majority funder of all public hospitals and taking full control of doctors and frontline health services in Australia. For the first time the government would directly pay hospitals to deliver treatment to patients.
The bill, designed to save taxpayers Euros 1.3 billion over the next five years is passing through the legislative process. Generics’ producers are unhappy with the medicines pricing component of the plans as they argue that they will face the brunt of the cuts.
At the moment the bill’s progress is stalled, and with a wafer-thin government majority, it is not clear when it will reach the statute books.
Related article
Price cuts, legislation and reforms
Reference
Pharmaceuticals in Australia. Datamonitor Healthcare. April 2010.
Source: Reuters
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Reports
FTC reveals extent of PBM drug mark-ups and profits
Latin American patients face 4.7-year wait for innovative treatments
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
NPRA Malaysia trials new timelines for variation applications

Home/Policies & Legislation Posted 05/11/2024
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US

Home/Policies & Legislation Posted 18/09/2024
China’s NMPA expands global ties with the Netherlands and Indonesia

Home/Policies & Legislation Posted 04/09/2024
Japan's PMDA expands influence with new office in Thailand

Home/Policies & Legislation Posted 06/08/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment